ARTICLE | Clinical News
FDA approves Kyowa's Poteligeo for CTCL
August 10, 2018 7:19 PM UTC
FDA approved Poteligeo mogamulizumab-kpkc from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat the two most common forms of cutaneous T cell lymphoma (CTCL).
The agency approved Poteligeo to treat adults with relapsed or refractory mycosis fungoides or Sézary syndrome who have already received one prior systemic therapy...
BCIQ Company Profiles
BCIQ Target Profiles